International Journal of Critical Illness and Injury Science

EDITORIAL
Year
: 2020  |  Volume : 10  |  Issue : 4  |  Page : 159--162

What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness


Andrew C Miller1, Shobi Venkatachalam2,  
1 Department of Emergency Medicine, Nazareth Hospital, Philadelphia, PA, USA
2 Department of Internal Medicine, Nazareth Hospital, Philadelphia, PA, USA

Correspondence Address:
Dr. Andrew C Miller
Department of Emergency Medicine, Nazareth Hospital, 2601 Holme Avenue, 3rd Floor, Marian Building, Philadelphia, PA 19152
USA




How to cite this article:
Miller AC, Venkatachalam S. What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.Int J Crit Illn Inj Sci 2020;10:159-162


How to cite this URL:
Miller AC, Venkatachalam S. What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness. Int J Crit Illn Inj Sci [serial online] 2020 [cited 2021 Jan 19 ];10:159-162
Available from: https://www.ijciis.org/text.asp?2020/10/4/159/305297


Full Text



Since emerging in December 2019, the coronavirus disease 2019 (COVID-19) pandemic caused by the beta-coronavirus severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) virus has resulted in over 66.5 million cases worldwide and over 1.53 million deaths (as of December 6, 2020). Roughly 20% of patients require hospitalization, with one-quarter of those necessitating intensive care unit (ICU) admission for reasons including refractory hypoxemia, shock, or multiple organ failure.[1],[2] The lack of therapies with data demonstrating efficacy resulted in many turning to less substantiated treatments supported by case reports or series, small nonrandomized studies, or even intellectual intuition. These have included (in part) antiviral therapies, immunomodulators, blood products, and traditional medications. This editorial focuses on one such therapy: intravenous immunoglobulin (IVIG) to treat severe or critical illness induced by COVID-19.

To date, seven human coronaviruses (CoV) have been identified.[2] Four of them are globally distributed and account for about 15% of common colds, whereas SARS-CoV, Middle-East Respiratory Syndrome CoV (MERS-CoV), and SARS-CoV-2 are zoonotic epidemic viruses that can cause severe respiratory infections and fatalities. CoV shares some morphological and functional properties that may be associated with cross-reactive immune responses, which may have important therapeutic implications.[3] A thorough discussion of the pathophysiology is outside the scope of this discussion, but interested readers may consider reviewing the included references.[3],[4] Cross-reactivity has been described among human CoVs of the same genus, particularly the beta-CoV, which include SARS-CoV, MERS-CoV, and SARS-CoV-2.[5],[6],[7]

IVIG preparations consist of highly purified immunoglobulins G (mostly IgG), obtained from 1000 to 15,000 healthy donors per batch.[8] It is frequently used for treating various autoimmune and inflammatory diseases. In general, the dose of IVIG for the therapeutic purposes is 2 g/kg infused for up to 5 consecutive days.[9] IVIG has been explored in over 100 diseases as an off-label drug. It exerts its therapeutic benefits by several mutually nonexclusive mechanisms targeting both soluble and cellular mediators of the inflammatory immune response.[9] The multitude of anti-inflammatory mechanisms, safety record, and preclinical data prompted clinical evaluation of IVIG in the management of severe and critically ill COVID-19 patients.[9]

In vitro studies supported the idea that, commercially, IVIG products contained antibodies with significant neutralization capacity against SARS-CoV-2 and SARS-CoV but not MERS.[3] After multiple case reports and series touted its efficacy, many began to use IVIG in the treatment of severe and critically ill COVID-19 patients, particularly for patients with central nervous system manifestations.[10],[11],[12],[13],[14],[15],[16],[17],[18] Of note, many of these cases had comorbid illnesses or chronically immunosuppressed states, for which IVIG may be an appropriate treatment,[10],[11],[18],[19] while others have touted high-dose IVIG pulse therapy as a means to prevent chronically immunosuppressed patients from contracting COVID-19.[20]

A listing of randomized and nonrandomized clinical studies in adult patients with severe or critical illness due to COVID-19 is presented in [Table 1], including two randomized[21],[22] and four nonrandomized clinical studies.[23],[24],[25],[26] Three studies were excluded from this review. The first, a randomized study, was excluded for quality concerns including high risk for reporting bias.[27] Data for all patients were only reported nonnumerically in graphical format, with numerical data reported for unplanned subgroup analyses. The second, a randomized study preprint, was excluded because it compared two experimental therapies (Anakinra/IVIG vs. Tocilizumab) without a control or usual care arm.[28] Finally, a nonrandomized study that compared early (<48 h) to late (≥48 h) IVIG treatment for COVID-19 was excluded because there was no non-IVIG treatment or usual care arm.[26] The risk of bias was assessed for each study using the ROBINS-I and GRADE tools.[29],[30]{Table 1}

The results of included studies are summarized in [Table 2]. Of note, when compared to usual care, IVIG treatment for COVID-19 has shown no benefit on hospital mortality (three studies, 973 patients, IVIG 196 (40.6%) versus usual care 186 (38.0%); evidence certainty High),[21],[22],[23],[24],[25] no benefit on 28-day mortality,[24],[25] and no benefit on 60-day mortality.[25] In addition, no benefit was observed for the need for invasive mechanical ventilation[22],[24] or ICU length-of-stay (LOS).[21],[22] Moreover, hospital LOS was longer with IVIG use (four studies, 1318 participants; evidence certainty Moderate).[21],[22],[24],[25] It should be noted that these data and conclusions should not be extrapolated to hyperimmune anti-COVID-19 IVIG. Investigations of this agent are currently planned or underway.[31],[32]{Table 2}

In conclusion, available evidence suggests that IVIG treatment for patients with severe or critical COVID-19 illness does not decrease hospital mortality and may prolong hospital LOS. Routine use of IVIG in severe or critically ill COVID-19 patients without other indications for its use is not advised.

References

1Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30:313-24.
2Stawicki S, Jeanmonod R, Miller A, Paladino L, Gaieski D, Yaffee A, et al. The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. J Glob Infect Dis 2020;12:47.
3Díez JM, Romero C, Alert VJ, Perez BM, Rodon J, Honrubia JM, et al. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins. Immunotherapy 2020;12:1247-55.
4Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: The known mechanisms and clinical effects. Front Immunol 2020;11:1660.
5Patrick DM, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden M, et al. An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus. Can J Infect Dis Med Microbiol 2006;17:330-6.
6Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013;67:130-40.
7Che X, Qiu L, Liao Z, Wang Y, Wen K, Pan Y, et al. Antigenic cross-reactivity between severe acute respiratory syndrome–associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis 2005;191:2033-7.
8Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020;19:102559. PMID: 32361195.
9Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunol 2020;9:e1198.
10Mohtadi N, Ghaysouri A, Shirazi S, Sara Ansari, Shafiee E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology 2020;548:1-5.
11Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol 2020;125:349-50.
12Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol 2020;267:2799-802.
13El-Zein RS, Cardinali S, Murphy C, Keeling T. COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin. BMJ Case Rep 2020;13:e237364. PMID: 32807652.
14Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents 2020;56:105974. PMID: 33214093.
15Muccioli L, Pensato U, Bernabè G, Ferri L, Tappatà M, Volpi L, et al. Intravenous immunoglobulin therapy in COVID-19-related encephalopathy. J Neurol 2020. Available from: http://link.springer.com/10.1007/s00415-020-10248-0. [Last accessed on 2020 Jun 12].
16Lanza M, Polistina GE, Imitazione P, Annunziata A, Di Spirito V, Novella C, et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. IDCases 2020;21:e00794.
17Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7:ofaa102.
18Erdogan C, Ciftci B, Kizilaslan D, Ekinci M, İptec G, Gemici Aİ, et al. High-dose intravenous immunoglobulin therapy for novel coronavirus disease 2019: A brief report of two cases. Ain-Shams J Anesthesiol 2020;12:39.
19Tatar E, Karatas M, Bozaci I, Ari A, Acar T, Simsek C, et al. Intravenous immunoglobulin and favipiravir treatment for a kidney transplant patient with severe Covid-19 pneumonia. Transfus Apher Sci 2020:102904. PMID: 32344202
20Prada V, Benedetti L, Cocito D, Briani C, Orazio NE, Gallia F, et al. High-dose immunoglobulin pulse therapy and risk of Covid19 infection. J Neurol 2020. Available from: http://link.springer.com/10.1007/s00415-020-10146-5. [Last accessed on 2020 Jun 12].
21Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 2020;20:786.
22Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol 2020:107205. PMID: 32807652.
23Esen F, Özcan PE, Orhun G, Polat Ö, Anaklı İ, Alay G, et al. Effects of adjunct treatment with intravenous Octagam on the course of severe COVID-19: Results from a retrospective cohort study. Curr Med Res Opin 2020. PMID: 33214093. Available from: https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1856058. [Last accessed on 2020 Jun 12].
24Liu J, Chen Y, Li R, Dong X, Li Y, Xu Q, et al. Intravenous immunoglobulin treatment for patients with severe COVID-19: A retrospective multi-center study. Research Square 2020. Available from: https://www.researchsquare.com/article/rs-52428/v1. [Last accessed on 2020 Jun 12].
25Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: A multicenter retrospective cohort study. Clin Transl Immunol 2020;9:e1192.
26Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020;81:318-56.
27Sakoulas G, Geriak M, Kullar R, Greenwood K, Habib M, Vyas A, et al. Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: A prospective randomized trial. medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.07.20.20157891v1. [Last accessed on 2020 Jun 12].
28Zanath M, Castillo ED, Gangemi AJ, Patel M, Chowdhury J, Verga S, et al. Anakinra and intravenous igg versus tocilizumab in the treatment of COVID-19 pneumonia. medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.09.11.20192401v1. [Last accessed on 2020 Jun 12].
29Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
30Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
31Ali S, Luxmi S, Anjum F, Muhaymin SM, Uddin SM, Ali A, et al. Hyperimmune anti-COVID-19 IVIG (C-IVIG) therapy for passive immunization of severe and critically ill COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials 2020;21:905.
32Esen F, Özcan PE, Orhun G, Polat Ö, Anaklı İ, Alay G, et al. Effects of adjunct treatment with intravenous Octagam on the course of severe COVID-19: Results from a retrospective cohort study. Curr Med Res Opin 2020;1. Available from: https://www.tandfonline.com/doi/ full/10.1080/03007995.2020.1856058. [Last accessed on 2020 Jun 12]. PMID: 33236646.